Post-induction MRD by FCM and GATA1-PCR are significant prognostic factors for myeloid leukemia of Down syndrome-Reference-Cited by-同舟云学术

Post-induction MRD by FCM and GATA1-PCR are significant prognostic factors for myeloid leukemia of Down syndrome

Published:2021-02-15 Issue:9 Volume:35 Page:2508-2516
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Taga Takashi^ORCID,Tanaka Shiro,Hasegawa Daisuke^ORCID,Terui Kiminori,Toki Tsutomu^ORCID,Iwamoto Shotaro^ORCID,Hiramatsu Hidefumi^ORCID,Miyamura Takako^ORCID,Hashii Yoshiko,Moritake Hiroshi^ORCID,Nakayama Hideki^ORCID,Takahashi Hiroyuki^ORCID,Shimada Akira,Taki Tomohiko,Ito Etsuro^ORCID,Hama Asahito^ORCID,Ito Masafumi,Koh Katsuyoshi^ORCID,Hasegawa Daiichiro,Saito Akiko M.,Adachi Souichi,Tomizawa Daisuke^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Cancer Research,Hematology

Link

https://www.nature.com/articles/s41375-021-01157-w.pdf

Reference14 articles.

1. Uffmann M, Rasche M, Zimmermann M, von Neuhoff C, Creutzig U, Dworzak M, et al. Therapy reduction in patients with Down syndrome and myeloid leukemia: the international ML-DS 2006 trial. Blood .2017;129:3314–21.

2. Taub JW, Berman JN, Hitzler JK, Sorrell AD, Lacayo NJ, Mast K, et al. Improved outcomes for myeloid leukemia of Down syndrome: a report from the Children’s Oncology Group AAML0431 trial. Blood .2017;129:3304–13.

3. Taga T, Watanabe T, Tomizawa D, Kudo K, Terui K, Moritake H, et al. Preserved high probability of overall survival with significant reduction of chemotherapy for myeloid leukemia in Down syndrome: a nationwide prospective study in Japan. Pediatr Blood Cancer. 2016;63:248–54.

4. Taga T, Saito AM, Kudo K, Tomizawa D, Terui K, Moritake H, et al. Clinic al characteristics and outcome of refractory/relapsed myeloid leukemia in children with Down syndrome. Blood. 2012;120:1810–5.

5. Gamis AS, Woods WG, Alonzo TA, Buxton A, Lange B, Barnard DR, et al. Increased age at diagnosis has a significantly negative effect on outcome in children with Down syndrome and acute myeloid leukemia: a report from the Children’s Cancer Group Study 2891. J Clin Oncol. 2003;21:3415–22.

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Azacitidine treatment for myeloid leukemia associated with Down syndrome: A nationwide retrospective study in Japan;Pediatric Blood & Cancer;2024-08-04

2. Guideline for treating relapsed or refractory myeloid leukemia in children with Down syndrome;Pediatric Blood & Cancer;2024-07-04

3. Landscape of driver mutations and their clinical effects on Down syndrome–related myeloid neoplasms;Blood;2024-06-20

4. Down syndrome-associated leukaemias: current evidence and challenges;Therapeutic Advances in Hematology;2024-01

5. Indication of allogeneic hematopoietic cell transplantation for patients with acute myeloid leukemia: from a pediatrician’s view;Japanese Journal of Transplantation and Cellular Therapy;2024